to Assess the Efficacy and Safety of the Probiotic E. Coli Strain M17 on Patients With GERD

The recruitment status of this study is unknown because the information has not been verified recently.
Verified May 2006 by BioBalance Corporation.
Recruitment status was  Not yet recruiting
Sponsor:
Information provided by:
BioBalance Corporation
ClinicalTrials.gov Identifier:
NCT00324532
First received: May 9, 2006
Last updated: NA
Last verified: May 2006
History: No changes posted
  Purpose

The study is an Open Label, Prospective, Non Comparative, Pilot, clinical trial design. Patients with inadequate relief in GI symptoms associated with GERD despite PPI treatment will be screened and those who meet the inclusion and exclusion criteria will perform a glucose breath test for bacterial overgrowth . Each patient will then complete a questionnaire to record their GERD related symptoms. Each patient will then receive a daily intake of 30 mL two times daily, 30 minutes before meals for a period of 4 weeks. During the course of the trial, they will have 4 visits with the study physician to assess treatment compliance and occurrence of adverse events, and will complete periodic daily diaries to record compliance.


Condition Intervention Phase
GERD
Drug: ProBactrix
Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open Label, Non Comparative, Prospective Pilot Study, to Assess the Efficacy and Safety of the Probiotic E. Coli Strain M17 on Patients With GERD

Further study details as provided by BioBalance Corporation:

Primary Outcome Measures:
  • improvement in one or more GI symptoms (heartburn, regurgitation, bloating, epigastric pain, abdominal pain and general well being).

Secondary Outcome Measures:
  • symptomatic response comparison between patients with a positive versus negative breath test for bacterial overgrowth
  • negative breath test for bacterial overgrowth in the patients with positive breath test at entry
  • safety

Estimated Enrollment: 60
Study Start Date: May 2006
Estimated Study Completion Date: May 2007
  Eligibility

Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Age between ≥18 and ≤80, males and females.
  2. Patient administered PPI therapy for GERD.
  3. Patient suffers from any GI symptoms including GERD symptoms despite PPI therapy for at least 60 days
  4. Patient with positive or negative glucose breath test for bacterial overgrowth unless they are not able to do this secondary to diabetes. Diabetics will have a lactulose breath test
  5. Able to give informed consent
  6. Candidate will be available for the next 4 weeks

Exclusion Criteria:

1. Pregnant, breast-feeding, or not using approved methods of contraception (if of childbearing potential) 2. Unstable medical disorder 3. Patient has had E. coli strain M17 administered in the past month 4. History of major psychiatric disorder or substance abuse within the previous 2 years, including psychiatric illnesses requiring medication that may cause doubt in the validity of the signed Informed Consent form 5. Existing illness or medical condition that will prevent the patient from participating in the study (such as severe heart disease, insulin dependent diabetes, hyperactive thyroid gland, HIV positive, etc.) 6. Participation in another clinical study during the past four weeks. 7. Any use of a probiotic supplement within 30 days of the screening period (with the exception of standard food yogurt products) 8. Any use of antibiotics within 30 days of the screening/enrollment period (however, candidate may wait to initiate screening exam until 30 days have lapsed since antibiotic course was completed)

-

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00324532

Contacts
Contact: D Braverman, Prof. gastro@szmc.org.il

Locations
Israel
Shaarei Zedek Medical Center Not yet recruiting
Jerusalem, Israel
Contact: Braverman       gastro@szmc.org.il   
Sponsors and Collaborators
BioBalance Corporation
Investigators
Principal Investigator: Braverman Shaarei Zedek Medical Center
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00324532     History of Changes
Other Study ID Numbers: BB 07 2005
Study First Received: May 9, 2006
Last Updated: May 9, 2006
Health Authority: Israel: Israeli Health Ministry Pharmaceutical Administration

Additional relevant MeSH terms:
Gastroesophageal Reflux
Esophageal Motility Disorders
Deglutition Disorders
Esophageal Diseases
Gastrointestinal Diseases
Digestive System Diseases

ClinicalTrials.gov processed this record on April 17, 2014